Olanzapine and obsessive–compulsive symptoms

  title={Olanzapine and obsessive–compulsive symptoms},
  author={Lefteris Lykouras and Ioannis M. Zervas and Rossetos Gournellis and Meni Malliori and A. Rabavilas},
  journal={European Neuropsychopharmacology},
Reduced short‐term obsessive–compulsive symptoms in schizophrenic patients treated with risperidone: a single‐blind prospective study
A number of case reports have suggested an increase in obsessive–compulsive symptoms in patients treated with risperidone, which is a widely used agent as first‐line treatment in schizophrenia with a favorable side‐effect profile.
Comorbidity: Schizophrenia With Obsessive-Compulsive Disorder
The co-occurrence of obsessive-compulsive symptoms (OCS) and psychotic illness has been a challenge for clinicians and investigators for more than a century. Over the past decade, interest in this
Obsessive–compulsive symptoms induced by atypical antipsychotics. A review of the reported cases
The Paradox of Quetiapine in Obsessive-Compulsive Disorder
This paradoxically induced OCD symptomology in schizophrenia patients administered atypical neuroleptics is discussed from new pathophysiological and clinical perspectives and emphasizes the prognostic implications of OCS in schizophrenia and available therapies for this comorbidity.
Risperidone-Induced Obsessive-Compulsive Symptoms: A Series of Six Cases
Risperidone-induced obsessive-compulsive symptoms appear to be dose-dependent and are probably produced by serotoninergic-dopaminergic imbalance, and close monitoring of the patients receiving ris peridone, especially those vulnerable to the development of obsessive-Compulsive symptoms, may be of value.
Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
Four patients with childhood-onset obsessive compulsive disorder, and with partial or no response to SSRI treatment, who subsequently had a reduction of their symptoms with Adderall augmentation are described.
Obsessive-Compulsive Disorder in Schizophrenia
Findings of recent studies pertaining to the rate of occurrence of OCD or obsessive-compulsive symptoms (OCS) in schizophrenia and the clinical characterisation of the schizo-obsessive subtype are critically evaluated.
Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature
It is suggested that clozapine confers the greatest risk of OCS in schizophrenia, with 20 to 28 % of clozAPine-treated patients experiencing de novo OCS, in addition to 10 to 18 % incurring an exacerbation of pre-existing OCS.
Schizo-Obsessive Disorder: the Epidemiology, Diagnosis, and Treatment of Comorbid Schizophrenia and OCD
Clinician awareness of the co-occurrence of obsessive–compulsive and psychotic symptoms is important for early identification and treatment of both and there is a need for valid and reliable diagnostic instruments in this population of patients.


Exacerbation of Obsessive–Compulsive Symptoms Associated with Clozapine
We report a case in which clozapine caused a marked and disabling exacerbation of obsessive–compulsive rituals in a patient with schizophrenia.
Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients.
It appears that disabling OC symptoms may occur as in response to clozapine treatment in chronic drug-resistant schizophrenic patients, and some of the latter may benefit from the addition of an SSRI to the ongoing clozAPine regimen.
Development of Obsessive-Compulsive Symptoms during Clozapine Treatment in Schizophrenia and Its Positive Response to Clomipramine
The arising of obsessive-compulsive symptoms during clozapine treatment of schizophrenia has been described by several clinicians although recently criticised, and anti-obsessive drug trials were made as add-on.
Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
It is suggested that clozapine monotherapy is not effective for most adult patients with treatment-resistant obsessive-compulsive disorder.
Fluoxetine and side effects.
An increased risk of extrapyramidal signs and symptoms during treatment with fluoxetine or other potent and selective inhibitors of neuronal uptake of serotonin is reported, and the ability of serotonin uptake blockers to potentiate putative inhibitory effects of serotonin on the metabolic production or release of dopamine by neurons of the basal ganglia is predicted.
Polyserositis associated with clozapine treatment.
Obsessive–compulsive symptoms and clozapine